SHANDONG XINHUA (00719) surged more than 4%, reaching HK$7.05 by the time of writing, with a trading volume of HK$19.36 million. The rally follows the latest announcement from China's National Medical Products Administration (NMPA) on November 24, approving the market launch of the company's Lidocaine and Prilocaine Cream under the registration category 4, which is considered equivalent to passing evaluation.

Lidocaine and Prilocaine Cream is a compound formulation of lidocaine and prilocaine, primarily used for local anesthesia on intact skin and as a pretreatment for superficial surgical procedures on genital mucosa. Compared to traditional anesthetics, it offers advantages such as convenience, higher safety, and non-dependency.